Patent 12004995 was granted and assigned to Allergan, Inc. on June, 2024 by the United States Patent and Trademark Office.
Biodegradable intraocular implants with a high loading of a prostamide compound for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.